Biotech Values

[DewDiligence]

any thoughts on ABT here? Not reacting well to the earnings? Anything stick out at you?

ABT is (IMO) being improperly penalized by investors for the patent-expiration cliff it does not have. I.e., there’s guilt by association from the fact that ABT is perceived as a member of Big Pharma and everyone knows that Big Pharma has patent-expiration issues.

I’ll post again after listening to ABT’s 4Q10 CC if I hear anything of consequence.